Background and objective: The exact role of the cystic fibrosis transmembrane conductance
regulator (CFTR) in pathophysiology, and the mechanisms regulating its expression are …

Aim: Several urinary hypermethylation-markers (hmDNA) have been described for bladder
cancer (BC) detection, but none have been able to replace cystoscopy yet. We …

A compelling body of evidences sustains the importance of epigenetic mechanisms in the
development and progression of cancer. Assessing the epigenetic component of bladder …

Bladder cancer (BC) is classified as non-muscle-invasive BC (NMIBC) or muscle-invasive
BC (MIBC). Because the recurrence and mortality rates of BC are high, suitable biomarkers …

Tissue-specific gene methylation events are key to the pathogenesis of several diseases
and can be utilized for diagnosis and monitoring. Here, we established an in silico pipeline …

To identify novel abnormally methylated genes in early stage non-small cell lung cancer
(NSCLC), we analyzed the methylation status of 13 genes (ALX1, BCL2, FOXL2, HPP1 …

Purpose Cystic fibrosis transmembrane conductance regulator (CFTR) was shown to be
downregulated or silenced in carcinomas and acts as a candidate tumor suppressor gene …

Epigenetic alterations by promoter DNA hypermethylation and gene silencing in cancer
have been reported over the past few decades. DNA hypermethylation has great potential to …

Bladder cancer (BC) is the second most common malignancy of the genitourinary tract and
the second leading cause of cancer death in patients with urinary tract malignancies. DNA …

Objective Noninvasive biomarkers are used routinely in the clinical management of several
cancers but bladder cancer detection and surveillance remains dependent on invasive …